Baldness treatment co gets $5.5m:
This article was originally published in Clinica
Follica, a Boston, Massachusetts firm developing a technology for treating hair loss caused by androgens in genetically susceptible men and women, has closed a $5.5m Series A financing round. The fundraising was led by Interwest Partners, and included the participation of existing investor PureTech Ventures participated. The new capital will take the company through a clinical proof-of-concept study. Follica's technology is designed to create and manipulate hair follicles in sufferers of androgenetic alopecia, a condition that affect around 50% of men and women in the US by the age of 50. The company said its technology can also be developed for treating other hair loss conditions and follicle-related disorders such as acne.
You may also be interested in...
Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.
Cambridge Nutraceuticals - which develops dietary supplements that have “proven clinical benefits” - has snapped up UK-based Prime Fifty to enhance its offering with products specifically designed for the over 50s.
Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.